Pegylated interferon (PEG-IFN)

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC, Peregrine Pharmaceuticals, Eisai Inc.

Conditions

Chronic Hepatitis C VirusHepatitis CHepatitis C, ChronicThrombocytopenia

Phase 1

Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

CompletedNCT01273948

Peregrine PharmaceuticalsHepatitis C

Start: 2011-01-31End: 2012-02-29Updated: 2012-02-06

Phase 2

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

CompletedNCT00704405

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2009-03-27End: 2012-09-10Updated: 2018-10-09

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

CompletedNCT00880763

Merck Sharp & Dohme LLCHepatitis C

Start: 2009-04-20End: 2012-02-23Updated: 2018-10-09

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

CompletedNCT01355289

Eisai Inc.Thrombocytopenia

Start: 2011-11-30End: 2014-05-31Updated: 2018-02-22

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

CompletedNCT01852604

Merck Sharp & Dohme LLCChronic Hepatitis C Virus

Start: 2013-03-31End: 2015-04-30Updated: 2015-04-23

Related Papers

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.

2014-08-1311 citations

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.

2013-10-1018 citations